Drugs / EYC-0305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07587515 | May 2026 → May 2028 expected | wet macular degeneration | Eyconis INC. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-18 | Eyconis INC. | Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients eyconis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYC-0305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587515 ↗ |
| Route | Intravitreal | “EYC-0305 delivered by intravitreal (IVT) injection” NCT07587515 ↗ |